Bio-Rad Laboratories, Inc. (BIO) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2026
Loading P/E history...
BIO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Bio-Rad Laboratories, Inc. (BIO) trades at a price-to-earnings ratio of 9.3x, with a stock price of $259.02 and trailing twelve-month earnings per share of $6.26.
The current P/E is 36% below its 5-year average of 14.5x. Over the past five years, BIO's P/E has ranged from a low of 3.4x to a high of 65.7x, placing the current valuation at the 55th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, BIO trades at a 58% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, BIO trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BIO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BIO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $176B | 26.7Lowest | 12.62 | +7% | |
| $124B | 34.7 | - | -5% | |
| $6B | 55.7 | - | -74% | |
| $7B | 146.2 | - | +287%Best | |
| $46B | 44.3 | 3.10Best | +23% | |
| $17B | 30.5 | - | -25% | |
| $7B | 90.7 | - | -76% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
BIO Historical P/E Data (1990–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $278.75 | $6.07 | 45.9x | +49% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $302.99 | $27.91 | 10.9x | -65% |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $241.32 | $11.73 | 20.6x | -33% |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $755.57 | $140.07 | 5.4x | -83% |
| FY2021 Q3 | $745.95 | $220.47 | 3.4x | -89% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $644.29 | $134.15 | 4.8x | -84% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $571.17 | $135.98 | 4.2x | -86% |
| FY2020 Q4 | $582.94 | $126.32 | 4.6x | -85% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $515.46 | $116.82 | 4.4x | -86% |
| FY2020 Q2 | $451.49 | $64.50 | 7.0x | -77% | |
| FY2020 Q1 | $350.56 | $52.21 | 6.7x | -78% | |
| FY2019 Q4 | $370.03 | $58.23 | 6.4x | -79% |
Average P/E for displayed period: 30.8x
See BIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBIO — Frequently Asked Questions
Quick answers to the most common questions about buying BIO stock.
Is BIO stock overvalued or undervalued?
BIO trades at 9.3x P/E, below its 5-year average of 14.5x. At the 55th percentile of historical range, the stock is priced at a discount to its own history.
How does BIO's valuation compare to peers?
Bio-Rad Laboratories, Inc. P/E of 9.3x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is BIO's PEG ratio?
BIO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2026.